Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$158.56 USD
-2.08 (-1.29%)
Updated Jul 29, 2024 04:00 PM ET
Pre-Market: $158.10 -0.46 (-0.29%) 8:16 AM ET
4-Sell of 5 4
C Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
JNJ 158.56 -2.08(-1.29%)
Will JNJ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JNJ
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Other News for JNJ
Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), Sotera Health (SHC) and Hologic (HOLX)
Johnson & Johnson (JNJ) Receives a Buy from RBC Capital
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
IN BRIEF: J&J subsidiary's Rybrevant recommended for further approval
AbbVie: Growth Is Still A Better Choice